Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €7.78 EUR
Change Today -0.079 / -1.01%
Volume 0.0
A8C1 On Other Exchanges
As of 2:08 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

abcam plc (A8C1) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/19/15 - €8.64
52 Week Low
10/16/14 - €4.55
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ABCAM PLC (A8C1)

Related News

No related news articles were found.

abcam plc (A8C1) Related Businessweek News

No Related Businessweek News Found

abcam plc (A8C1) Details

Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools in the United States, Japan, Germany, the United Kingdom, China, and internationally. The company primarily offers primary and secondary antibodies, biochemicals, isotype controls, flow cytometry multi-color selectors, kits, loading controls, lysates, peptides, proteins, slides, tags and cell markers, tools and reagents, and immunoassay kits and reagents. Its products are used in the areas of cancer, cardiovascular, cell biology, epigenetics and nuclear signaling, metabolism, developmental biology, immunology, microbiology, neuroscience, signal transduction, and stem cells, as well as in drug discovery products and services. The company also sells its products through the Internet. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

820 Employees
Last Reported Date: 10/2/15
Founded in 1998

abcam plc (A8C1) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 642.0K GBP
Co-Founder and Non-Executive Deputy Chairman
Total Annual Compensation: 147.0K GBP
Chief Financial Officer, Executive Director a...
Total Annual Compensation: 525.0K GBP
Chief Operating Officer, Executive Director a...
Total Annual Compensation: 538.0K GBP
Compensation as of Fiscal Year 2015.

abcam plc (A8C1) Key Developments

Abcam plc Announces Launch of its Anti-PD-L1 Primary Antibody

Abcam plc announced the launch of its anti-PD-L1 primary antibody (clone 28-8). Produced using Abcam's RabMAb recombinant monoclonal antibody technology, the clone offers highly specific and reproducible antigen recognition to a checkpoint inhibitor critical to current cancer immunology research. Programmed-death ligand 1 (PD-L1), also known as CD274 and B7-H1, can be expressed on the surface of tumour cells and binds to PD-1 receptors found on T-cells. This mechanism is used by tumour cells to evade detection and removal by the immune system. Abcam’s highly specific anti-PD-L1 clone (clone 28-8) has been knockout validated and tested in key applications such as Immunohistochemisty (IHC)1 and Flow Cytometry providing researchers with trusted data and ensuring the accuracy of their results. Developed through a research collaboration with a major pharma company, the PD-L1 antibody will give researchers a high quality tool to further explore the role of PD-L1 in disease progression and treatment. An IHC assay using clone 28-8 has been used to determine PD-L1 expression in clinical trials. Aside from cancer immunology, PD-L1 has also been implicated as having a role in autoimmune diseases and neurological disease. Abcam is planning further industry partnerships, applying its RabMAb primary antibody technology to make emerging biomarkers available for major disease areas for both research and diagnostic purposes, including other checkpoint inhibitors. RabMAb primary antibodies offer researchers the sensitivity of the rabbit immune system combined with the specificity and consistency of monoclonal antibodies.

Abcam Plc, 2015 Earnings Call, Sep 14, 2015

Abcam Plc, 2015 Earnings Call, Sep 14, 2015

Abcam plc Announces Directorate Changes

Abcam plc announced that Jeff Iliffe, CFO has served notice of his intention to step down from the Board, to move on to the next stage of his career outside Abcam within the next 12 months. Jeff remains committed to the company and will work with the rest of the Board to help identify a suitable successor and to ensure an orderly transition is affected in due course. The company also announced the appointment of Mara Glickman Aspinall to the Board of the company as a Non-Executive Director, with immediate effect. Mara was the President and CEO of Ventana Medical Systems. Mara currently serves as Executive Chairman of GenePeeks Inc.; Director of Safeguard Scientifics, Castle Biosciences and Blue Cross Blue Shield Arizona.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
A8C1:GR €7.78 EUR -0.079

A8C1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.71 USD -0.04
Becton Dickinson and Co $137.76 USD +0.64
Bio-Techne Corp $94.42 USD +0.73
Enzo Biochem Inc $3.75 USD +0.04
Sigma-Aldrich Corp $139.65 USD +0.04
View Industry Companies

Industry Analysis


Industry Average

Valuation A8C1 Industry Range
Price/Earnings 30.7x
Price/Sales 7.9x
Price/Book 5.3x
Price/Cash Flow 30.7x
TEV/Sales 8.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABCAM PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at